WHO classification of tumors of hematopoietic and lymphoid tissues

Radiopaedia • CC-by-nc-sa 3.0 • de

The World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues is the most widely used pathologic classification system for hematolymphoid neoplasms. The current revision, known as the 4 revised edition, was published in 2016 and supersedes the 4edition published in 2008.

The current 2016 version forms the basis of the article below .

Classification

Myeloid neoplasms
  • myeloproliferative neoplasms
  • mastocytosis
    • cutaneous mastocytosis
    • systemic mastocytosis
      • indolent systemic mastocytosis
      • smoldering systemic mastocytosis
      • systemic mastocytosis with an associated hematological neoplasm
      • aggressive systemic mastocytosis
      • mast cell leukemia
    • mast cell sarcoma
  • myeloid/lymphoid neoplasms with eosinophilia and gene rearrangement
    • myeloid/lymphoid neoplasms with PDGFRA rearrangement
    • myeloid/lymphoid neoplasms with PDGFRB rearrangement
    • myeloid/lymphoid neoplasms with FGFR1 rearrangement
    • myeloid/lymphoid neoplasms with PCM1-JAK2 (provisional entity)
  • myelodysplastic/myeloproliferative neoplasms
    • chronic myelomonocytic leukemia
    • atypical chronic myeloid leukemia, BCR-ABL1-negative
    • juvenile myelomonocytic leukemia
    • myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
    • myelodysplastic/myeloproliferative neoplasm, unclassifiable
  • myelodysplastic syndromes
    • myelodysplastic syndrome with single lineage dysplasia
    • myelodysplastic syndrome with multilineage dysplasia
    • myelodysplastic syndrome with ring sideroblasts
      • myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia
      • myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia
    • myelodysplastic syndrome with excess blasts
    • myelodysplastic syndrome with isolated del(5q)
    • myelodysplastic syndrome, unclassifiable
    • refractory cytopenia of childhood (provisional entity)
  • myeloid neoplasms with germline predisposition
    • myeloid neoplasms with germline predisposition without a preexisting disorder or organ dysfunction
      • acute myeloid leukemia with germline CEBPA mutation
      • myeloid neoplasms with germline DDX41 mutation
    • myeloid neoplasms with germline predisposition and preexisting platelet disorders
      • myeloid neoplasms with germline RUNX1 mutation
      • myeloid neoplasms with germline ANKRD26 mutation
      • myeloid neoplasms with germline ETV6 mutation
    • myeloid neoplasms with germline predisposition and other organ dysfunction
      • myeloid neoplasms with germline GATA2 mutation
      • myeloid neoplasms associated with bone marrow failure syndromes
      • myeloid neoplasms associated with telomere biology disorders
      • juvenile myelomonocytic leukemia associated with neurofibromatosis, Noonan syndrome or Noonan syndrome-like disorders
      • myeloid neoplasms associated with Down syndrome
  • acute myeloid leukemia and related neoplasms
    • acute myeloid leukemia with recurrent genetic abnormalities
      • acute myeloid leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1
      • acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
      • acute promyelocytic leukemia with PML-RARA
      • acute myeloid leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A
      • acute myeloid leukemia with t(6;9)(p23;q34.1); DEK-NUP214
      • acute myeloid leukemia with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
      • acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-MKL1
      • acute myeloid leukemia with BCR-ABL1 (provisional entity)
      • acute myeloid leukemia with mutated NPM1
      • acute myeloid leukemia with biallelic mutations of CEBPA
      • acute myeloid leukemia with mutated RUNX1 (provisional entity)
    • acute myeloid leukemia with myelodysplasia-related changes
    • therapy-related myeloid neoplasms
    • acute myeloid leukemia, not otherwise specified
      • acute myeloid leukemia with minimal differentiation
      • acute myeloid leukemia without maturation
      • acute myeloid leukemia with maturation
      • acute myelomonocytic leukemia
      • acute monoblastic/monocytic leukemia
      • pure erythroid leukemia
      • acute megakaryoblastic leukemia
      • acute basophilic leukemia
      • acute panmyelosis with myelofibrosis
    • myeloid sarcoma
    • myeloid proliferations related to Down syndrome
      • transient abnormal myelopoiesis
      • myeloid leukemia associated with Down syndrome
  • blastic plasmacytoid dendritic cell neoplasm
  • acute leukemias of ambiguous lineage
    • acute undifferentiated leukemia
    • mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
    • mixed phenotype acute leukemia with t(v;11q23.3); KMT2A rearranged
    • mixed phenotype acute leukemia, B/myeloid, not otherwise specified
    • mixed phenotype acute leukemia, T/myeloid, not otherwise specified
Lymphoid neoplasms
  • precursor lymphoid neoplasms
    • B-lymphoblastic leukemia/lymphoma
      • B-lymphoblastic leukemia/lymphoma, not otherwise specified
      • B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities
        • B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1
        • B-lymphoblastic leukemia/lymphoma with t(v;11q23.3); KMT2A rearranged
        • B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); ETV6-RUNX1
        • B-lymphoblastic leukemia/lymphoma with hyperdiploidy
        • B-lymphoblastic leukemia/lymphoma with hypodiploidy
        • B-lymphoblastic leukemia/lymphoma with t(5;14)(q31.1;q32.3); IL3-IGH
        • B-lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1
        • B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like (provisional entity)
        • B-lymphoblastic leukemia/lymphoma with iAMP21 (provisional entity)
    • T-lymphoblastic leukemia/lymphoma
      • early T-cell precursor lymphoblastic leukemia (provisional entity)
    • natural killer (NK) cell lymphoblastic leukemia/lymphoma (provisional entity)
  • mature B-cell neoplasms
  • mature T- and NK-cell neoplasms
    • T-cell prolymphocytic leukemia
    • T-cell large granular lymphocytic leukemia
    • chronic lymphoproliferative disorder of NK cells (provisional entity)
    • aggressive NK-cell leukemia
    • EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood
      • systemic EBV-positive T-cell lymphoma of childhood
      • chronic active EBV infection of T- and NK-cell type, systemic form
      • hydroa vacciniforme–like lymphoproliferative disorder
      • severe mosquito bite allergy
    • adult T-cell leukemia/lymphoma
    • extranodal NK-/T-cell lymphoma, nasal type
    • intestinal T-cell lymphoma
      • enteropathy-associated T-cell lymphoma
      • monomorphic epitheliotropic intestinal T-cell lymphoma
      • intestinal T-cell lymphoma, not otherwise specified
      • indolent T-cell lymphoproliferative disorder of the gastrointestinal tract (provisional entity)
    • hepatosplenic T-cell lymphoma
    • subcutaneous panniculitis-like T-cell lymphoma
    • mycosis fungoides
    • Sézary syndrome
    • primary cutaneous CD30+ T-cell lymphoproliferative disorders
      • lymphomatoid papulosis
      • primary cutaneous anaplastic large cell lymphoma
    • primary cutanoue peripheral T-cell lymphomas, rare subtypes
      • primary cutaneous γδ T-cell lymphoma
      • primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (provisional entity)
      • primary cutaneous acral CD8+ T-cell lymphoma (provisional entity)
      • primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (provisional entity)
    • peripheral T-cell lymphoma, not otherwise specified
    • angioimmunoblastic T-cell lymphoma and other nodal lymphomas of T follicular helper cell origin
      • angioimmunoblastic T-cell lymphoma
      • follicular T-cell lymphoma (provisional entity)
      • nodal peripheral T-cell lymphoma with T follicular helper phenotype (provisional entity)
    • anaplastic large-cell lymphoma
      • anaplastic large-cell lymphoma, ALK-positive
      • anaplastic large-cell lymphoma, ALK-negative
    • breast implant-associated anaplastic large-cell lymphoma (provisional entity)
  • Hodgkin lymphoma
    • nodular lymphocyte predominant Hodgkin lymphoma
    • classical Hodgkin lymphoma
      • nodular sclerosis classical Hodgkin lymphoma
      • lymphocyte-rich classical Hodgkin lymphoma
      • mixed cellularity classical Hodgkin lymphoma
      • lymphocyte-depleted classical Hodgkin lymphoma
  • posttransplant lymphoproliferative disorders (PTLD)
    • plasmacytic hyperplasia PTLD
    • infectious mononucleosis PTLD
    • florid follicular hyperplasia PTLD
    • polymorphic PTLD
    • monomorphic PTLD
      • monomorphic B-cell PTLD
      • monomorphic T/NK-cell PTLD
    • classical Hodgkin lymphoma PTLD
Histiocytic and dendritic cell neoplasms
  • histiocytic sarcoma
  • tumors derived from Langerhans cells
  • indeterminate dendritic cell tumor
  • interdigitating dendritic cell sarcoma
  • follicular dendritic cell sarcoma
    • inflammatory pseudotumor-like follicular/fibroblastic dendritic cell sarcoma
  • fibroblastic reticular cell tumor
  • disseminated juvenile xanthogranuloma
  • Erdheim-Chester disease

See also

Siehe auch:
und weiter:
Assoziationen und Differentialdiagnosen zu WHO classification of lymphoma:
Multiples
Myelom
Wikipedia • CC BY-SA 3.0